We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical ...
With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...
Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.
Clinical Trials Arena on MSN4d
Amgen and Kyowa Kirin’s rocatinlimab trial for atopic dermatitis meets endpointsAmgen and Kyowa Kirin have reported that the 24-week Phase III IGNITE trial assessing two dose strengths of rocatinlimab, in ...
Michael Castagna became CEO of MannKind and joined its board of directors in 2017, bringing 25+ years’ experience in ...
Healthcare Analysts discuss Amgen’s ( AMGN) Late-Stage Pipeline In The Rare Autoimmune Disease Arena on an Analyst/Industry conference call to be held on March 7. Published first on TheFly – the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback